Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

5274 ARTÍCULOS , VIENDO DEL 3646 AL 3660

Striatal Induction and Spread of the Huntington's Disease Protein: A Novel Rhes Route

Subramaniam S.

J Huntingtons Dis. 2022;11(3):281-290. doi: 10.3233/JHD-220548.

Pallidus Stimulation for Chorea-Acanthocytosis: A Systematic Review and Meta-Analysis of Individual Data

He W, Li C, Dong H, Shao L, Yin B, Li D, Ye L, Hu P, Zhang C, Yi W.

J Mov Disord. 2022 Sep;15(3):197-205. doi: 10.14802/jmd.22003. Epub 2022 Jul 26.

New Frontiers in Neurodegeneration and Regeneration Associated with Brain-Derived Neurotrophic Factor and the rs6265 Single Nucleotide Polymorphism

Szarowicz CA, Steece-Collier K, Caulfield ME.

Int J Mol Sci. 2022 Jul 20;23(14):8011. doi: 10.3390/ijms23148011.

Effect of Immersive Virtual Reality by a Computer Assisted Rehabilitation Environment (CAREN) in Juvenile Huntington's Disease: A Case Report

Cellini R, Paladina G, Mascaro G, Lembo MA, Lombardo Facciale A, Ferrera MC, Fonti B, Pergolizzi L, Buonasera P, Bramanti P, Mazzon E.

Medicina (Kaunas). 2022 Jul 11;58(7):919. doi: 10.3390/medicina58070919.

GRIN2D-Related Developmental and Epileptic Encephalopathy

Platzer K, Krey I, Lemke JR.

2022 Jul 28. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews(®) [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2026.

Diabetic Striatopathy Complicated With Acute Ischemic Stroke: A Case Report

Huang X, Qi J, Li Y, Li J, Yang MG.

Front Neurosci. 2022 Jul 12;16:877479. doi: 10.3389/fnins.2022.877479. eCollection 2022.

Disaccharide trehalose in experimental therapies for neurodegenerative disorders: Molecular targets and translational potential

Pupyshev AB, Klyushnik TP, Akopyan AA, Singh SK, Tikhonova MA.

Pharmacol Res. 2022 Sep;183:106373. doi: 10.1016/j.phrs.2022.106373. Epub 2022 Jul 28.

Targeting Molecular Mediators of Ferroptosis and Oxidative Stress for Neurological Disorders

Li J, Jia B, Cheng Y, Song Y, Li Q, Luo C.

Oxid Med Cell Longev. 2022 Jul 22;2022:3999083. doi: 10.1155/2022/3999083. eCollection 2022.

[Dance therapy in the rehabilitation of neurological diseases]

Sivertseva SA, Anfilofeva KS, Zotova AV, Sherman MA, Guseva ME, Boyko AN.

Zh Nevrol Psikhiatr Im S S Korsakova. 2022;122(7. Vyp. 2):31-35. doi: 10.17116/jnevro202212207231.

A Review of Molecular Interplay between Neurotrophins and miRNAs in Neuropsychological Disorders

Abdolahi S, Zare-Chahoki A, Noorbakhsh F, Gorji A.

Mol Neurobiol. 2022 Oct;59(10):6260-6280. doi: 10.1007/s12035-022-02966-5. Epub 2022 Aug 2.

Therapeutic application of quercetin in aging-related diseases: SIRT1 as a potential mechanism

Cui Z, Zhao X, Amevor FK, Du X, Wang Y, Li D, Shu G, Tian Y, Zhao X.

Front Immunol. 2022 Jul 22;13:943321. doi: 10.3389/fimmu.2022.943321. eCollection 2022.

Natural Antioxidant Compounds as Potential Pharmaceutical Tools against Neurodegenerative Diseases

Marino A, Battaglini M, Moles N, Ciofani G.

ACS Omega. 2022 Jul 19;7(30):25974-25990. doi: 10.1021/acsomega.2c03291. eCollection 2022 Aug 2.

Very Long Time Persistent HyperCKemia as the First Manifestation of McLeod Syndrome: A Case Report

Torres V, Painous C, Santacruz P, Sánchez A, Sanz C, Grau-Junyent JM, Muñoz E.

Mov Disord Clin Pract. 2022 Jul 3;9(6):821-824. doi: 10.1002/mdc3.13502. eCollection 2022 Aug.

Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial

Feigin A, Evans EE, Fisher TL, Leonard JE, Smith ES, Reader A, Mishra V, Manber R, Walters KA, Kowarski L, Oakes D, Siemers E, Kieburtz KD, Zauderer M; Huntington Study Group SIGNAL investigators.

Nat Med. 2022 Oct;28(10):2183-2193. doi: 10.1038/s41591-022-01919-8. Epub 2022 Aug 8.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias